BIOTECH PHARMACEUTICAL CO., LTD

BIOTECH PHARMACEUTICAL CO., LTD (abbreviated as “BPL”), was founded in 2000. BPL is an early national high-tech enterprise engaged in the R&D, manufacturing and sales of innovative biological drugs such as monoclonal antibody and therapeutic vaccines.

BPL is an important strategic cooperation project between China and Cuba in the biopharmaceutical field. Nimotuzumab injection (Trade name: Taixinsheng®), BPL's self-developed new Class I biological drug and China’s first monoclonal antibody drug for the treatment of malignant tumors, has been on the Chinese market for more than 10 years. It was included in NCCN Clinical Practice Guidelines in Oncology (2010), as well as in the catalog of medicines covered by the Chinese national basic medical insurance in 2017. Several clinical studies for registration of Nimotuzumab are underway to expand its approved indications, which will benefit more patients with cancer and improve their survival benefits.